Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors

Inclusion Criteria: * Subjects must be ≥ than 6 months and ≤ 30 years of age at the time of study enrollment. * Subjects must have had histologic verification of a malignancy at original diagnosis or relapse. * All subjects with relapsed or refractory solid tumors are eligible, excluding primary CNS tumors. * Patients with solid tumors and a history of intraparenchymal CNS disease are eligible if their CNS disease was treated surgically or with radiotherapy and stable with no recurrent lesions for at least 3 months from the start of protocol therapy. * Newly diagnosed patients with ≤15% chance of cure if given standard-of-care chemotherapy are eligible. (Prognosis to be determined at the discretion of the treating physician.) * Subjects must have either measurable or evaluable disease. * Karnofsky ≥ 60 for subjects \> 16 years of age and Lansky ≥ 50 for subjects ≤ 16 years of age. Subjects who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score. * Subjects must have fully recovered from the acute toxic effects of all prior anti-cancer chemotherapy. * At least 21 days after the last dose of myelosuppressive chemotherapy (42 days if prior nitrosourea). * At least 14 days after the last dose of a long-acting growth factor (e.g. Pegfilgrastim) or 7 days for short acting growth factor. For agents that have known adverse events occurring beyond 7 days after administrat…